NasdaqGM - Nasdaq Real Time Price USD

Summit Therapeutics Inc. (SMMT)

Compare

17.83

-0.04

(-0.22%)

At close: December 13 at 4:00:01 PM EST

17.90

+0.07

(+0.39%)

After hours: 7:57:42 PM EST

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIAMI, December 13, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 98,000 shares of common stock. Awards were made to six new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committe

Business Wire 10 hours ago

SMMT
-0.22%
Here's Why Summit Therapeutics Stock Price Rose 6% on Friday

SMMT stock rose after analysts at Jefferies initiated coverage on it, citing optimism about the company's lead pipeline drug.

Zacks 4 days ago

SMMT
-0.22%
Why Summit Therapeutics Stock Rocketed 6% Higher on Friday

Summit Therapeutics (NASDAQ: SMMT) stock got a real shot in the arm Friday with the initiation of coverage by a veteran financial services company. On news that Jefferies is now tracking the stock, investors snapped it up to push its price nearly 6% higher across the day's trading session. Jefferies, in the person of analyst Hangfei Fu, launched its Summit coverage with a confident buy recommendation and a price target of $31 per share.

Motley Fool 7 days ago

SMMT
-0.22%
Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher

Thanks to the Securities and Exchange Commission, you don't have to. Artificial intelligence (AI) has been the stock market's dominant theme since ChatGPT began raising eyebrows a couple of years ago. From the end of 2022 through Nov. 1, 2024, shares of the AI data-mining specialist Palantir (NASDAQ: PLTR) rocketed 945% higher.

Motley Fool 11 days ago

SMMT
-0.22%
Warning: This Skyrocketing Stock Has a Hidden Risk

Although ivonescimab is approved for treating non-small cell lung cancer (NSCLC) by China's National Medical Products Administration, the Food and Drug Administration (FDA) in the U.S., or any other regulatory agency, is yet to approve it. Summit is thus performing a pair of phase 3 clinical trials in the U.S. testing the antibody for the same indications, hoping to generate a dataset that regulators at the FDA will find compelling enough to grant the approval for commercialization. A third phase 3 trial is planned, and it's expected to start in 2025.

Motley Fool 13 days ago

SMMT
-0.22%
Summit Therapeutics to Present at Upcoming Investor Conferences

MIAMI, November 26, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at the 7th Annual Evercore HealthCONx Conference and Citi’s 2024 Global Healthcare Conference, both being held in Miami. Our management team will participate in fireside chats surrounding the development of our innovative investigational bispecific antibody, ivonescimab, at the Evercore HealthCONx Conference on Tuesday December 3, 2024 at 8:

Business Wire 17 days ago

SMMT
-0.22%
3 Monster Stocks in the Making

Here's why they think biotech stocks CRISPR Therapeutics (NASDAQ: CRSP), Summit Therapeutics (NASDAQ: SMMT), and Viking Therapeutics (NASDAQ: VKTX) could become much larger. David Jagielski (CRISPR Therapeutics): If you're looking for stocks with mammoth upside, you might be tempted to look for risky stocks that don't have any approved drugs or treatments yet. In December 2023, regulators approved Casgevy, which is a gene-editing therapy the company has been developing with Vertex Pharmaceuticals.

Motley Fool 20 days ago

VKTX
-1.75%
SMMT
-0.22%
CRSP
Summit Therapeutics (SMMT) Hurt Bronte Capital. Here’s Why

Bronte Capital, an investment management company, released its “Amalthea Fund” third-quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund was down 3.72% for the quarter vs. +2.54% for the MSCI ACWI (in $A). It was down 5.59% in September vs. -0.35% for the index. The market rose in the […]

Insider Monkey 23 days ago

SMMT
-0.22%
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

Investor's Business Daily 29 days ago

MRK

SMMT
-0.22%
TipRanks’ ‘Perfect 10’ Picks: 2 Top-Scoring Stocks for the Rest of 2024

With the end of 2024 approaching, what could be more natural than to figure out the top stocks for the rest of the year? Stock picking of this sort is an essential skill for every investor, and fortunately, the Smart Score make it easier. This data gathering and sorting tool from TipRanks uses a combination of AI tech and natural language algorithms to gather and comb through the aggregated data of the stock market – data derived from thousands of traders dealing in thousands of stocks for tens

TipRanks last month

BOOT

SMMT
-0.22%
2 Hot Biopharma Stocks to Buy and Hold for 5 Years

If you're patient, these businesses have a lot of promising projects in the works.

Motley Fool last month

SMMT
-0.22%
Why Summit Therapeutics Stock Was a Winner Today

A cancer drug has vast potential for the company, says a pundit newly following it.

Motley Fool last month

SMMT
-0.22%
^GSPC
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo

JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious disease. Later, in 2022, the company pivoted to oncology and in-licensed ivonescimab (PD-1 X VEGF bispecific) from Akeso for $500 million upfront and $5 billion in potential milestones. The analyst says, “We believe Summit shares represent a unique investment opportunity.” Also Read: Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Stu

Benzinga last month

SMMT
-0.22%
Summit Therapeutics Leads the Parade of Big Gainers

A list of stocks that gained more than 200%

GuruFocus.com last month

SMMT
-0.22%
MSTR

CVNA
3 Magnificent Stocks Under $100 to Buy in November

The price could be right for these stocks.

Motley Fool last month

EXEL

AZN

SMMT
-0.22%
Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales

SMMT's third-quarter earnings miss estimates. Management also provides updates on the company's pipeline.

Zacks last month

SMMT
-0.22%
3 Stocks That Have Generated 1,000% Returns in Just 2 Years

Should you add these fast-growing stocks to your portfolio?

Motley Fool last month

NVDA

CVNA

SMMT
-0.22%
Summit Therapeutics Inc (SMMT) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

Summit Therapeutics Inc (SMMT) reports robust cash position and strategic progress with ivonescimab, despite rising expenses and competitive challenges.

GuruFocus.com last month

SMMT
-0.22%
Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insight

Insightful Analysis of Summit Therapeutics Inc's Financial Health and Strategic Position

GuruFocus.com last month

SMMT
-0.22%
Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024

MIAMI, October 30, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reported an update on its operational progress and financial results for the third quarter and nine months ended September 30, 2024.

Business Wire last month

SMMT
-0.22%

Performance Overview

Return	SMMT	S&P 500
YTD	+583.14%	+26.86%
1-Year	+710.45%	+30.31%
3-Year	+259.48%	+28.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Summit Therapeutics Inc. (SMMT)

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Here's Why Summit Therapeutics Stock Price Rose 6% on Friday

Why Summit Therapeutics Stock Rocketed 6% Higher on Friday

Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher

Warning: This Skyrocketing Stock Has a Hidden Risk

Summit Therapeutics to Present at Upcoming Investor Conferences

3 Monster Stocks in the Making

Summit Therapeutics (SMMT) Hurt Bronte Capital. Here’s Why

Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics

TipRanks’ ‘Perfect 10’ Picks: 2 Top-Scoring Stocks for the Rest of 2024

2 Hot Biopharma Stocks to Buy and Hold for 5 Years

Why Summit Therapeutics Stock Was a Winner Today

Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo

Summit Therapeutics Leads the Parade of Big Gainers

3 Magnificent Stocks Under $100 to Buy in November

Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales

3 Stocks That Have Generated 1,000% Returns in Just 2 Years

Summit Therapeutics Inc (SMMT) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insight

Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024

Performance Overview